Clinical Trials Logo

Clinical Trial Summary

Positron emission tomography (PET) is a non-invasive imaging tool for monitoring functional and metabolic responses of biological events with specific radiotracer in vivo. The PET tracer [18F]Fluciclatide is an 18F radiolabeled small peptide containing the RGD (arginine-glycine-aspartate) tri-peptide, which preferentially binds with high affinity to αvβ3 and αvβ5 integrins. αvβ3-integrins are expressed at low levels on epithelial cells and mature endothelial cells but are expressed at high levels on activated endothelial cells in the neo-vasculature of a range of tumors and it also may regulate angiogenesis. If pazopanib acts mainly on active angiogenetic tumors, the quantitative uptake of [18F]Fluciclatide can be used to predict the effect of this antiangiogenic drug. The investigators expected the baseline tumor uptake in [18F]Fluciclatide to be able to predict treatment response, and planned a study of [18F]FluciclatidePET for patients with metastatic RCC who received pazopanib systemic therapy.


Clinical Trial Description

Subjects will receive treatment with pazopanib at a dose of 800 mg orally once daily. [18F]Fluciclatide imagings will be taken 2 times; 1) before systemic therapy (at baseline), 2) at one week after starting of Pazopanib. However, If the target lesion on the baseline PET cannot be discriminated compared to the background activity, the 2nd PET will not be done. Response evaluation by CT will be performed at baseline, at 6 week, at 12 week and every 8 weeks thereafter until the end of treatment. RECIST1.1 criteria for response will be applied. Patient will be treated with Pazopanib until there is disease progression, unacceptable toxicity or withdrawal of patient consent. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT01961583
Study type Interventional
Source Asan Medical Center
Contact
Status Terminated
Phase Phase 2
Start date September 2013
Completion date April 2016

See also
  Status Clinical Trial Phase
Completed NCT00001302 - A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833 Phase 1
Completed NCT01896778 - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer N/A
Enrolling by invitation NCT02287987 - CLamp vs Off Clamp Kidney During Partial Nephrectomy N/A
Recruiting NCT04644432 - Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma Phase 2
Active, not recruiting NCT05817604 - Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
Completed NCT00888641 - A Pilot Study of Renal Hypothermia During Partial Nephrectomy Phase 1
Completed NCT00199875 - Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250 Phase 1
Recruiting NCT00994188 - A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members N/A
Recruiting NCT02346435 - The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Completed NCT01087060 - Detection of Renal Malignancy of Complicated Renal Cysts N/A
Recruiting NCT04258462 - Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors Phase 2
Recruiting NCT00898365 - Study of Kidney Tumors in Younger Patients
Recruiting NCT03996850 - SPECT/CT for the Characterization of Renal Masses
Recruiting NCT04823923 - Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer N/A
Not yet recruiting NCT04681690 - German National Registry for NSS
Not yet recruiting NCT05135832 - Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma N/A
Recruiting NCT04602702 - Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors
Terminated NCT00005655 - Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer Phase 1
Recruiting NCT05887245 - Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
Recruiting NCT06467097 - Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma Phase 3